Takeda's Shire deal draws ire of a top-10 shareholder — 4 insights

One of Takeda's largest shareholders is skeptical of the company's plan to acquire Shire for $62 billion, according to Bloomberg's coverage of a Sunday Times report.

Here's what you should know:

1. The deal has been met with disapproval from several shareholders. Now an unidentified top-10 investor raised concerns over the potential value the resulting combined company would have.

2. Another group of investors formed a group called "Thinking About Takeda's Future" to raise concerns about the deal.

3. Takeda shareholders previously voted down a proposal that would have required the company to get shareholder approval for any deal with more than $8.9 billion.

4. Takeda is completing the regulatory approval process before putting the acquisition to a formal shareholder vote.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.